Warar Degdeg ah
Qaab nololeed

Tel Aviv-Based Matricelf Reports Positive Safety Results for Spinal Cord Implant

Matricelf Ltd., a Tel Aviv-based regenerative medicine company, has completed a Good Laboratory Practice (GLP) safety study for its ...

tps.co.il

Maqaalkan waxaa si toos ah looga turjumay warbixinta asalka ah ee Ingiriisiga ee IsraelFM. Akhri maqaalka asalka ah ee Ingiriisiga

Jerusalem, 17 June, 2026 (TPS-IL) — Matricelf Ltd., a Tel Aviv-based regenerative medicine company, has completed a Good Laboratory Practice (GLP) safety study for its engineered neural tissue implant for spinal cord injury, moving it closer to a first-in-human clinical trial.

The study, conducted on 248 animals over a 39-week period, found no treatment-related toxicity, tumor formation, or implant migration. The results support the safety profile of the personalized therapy, which uses patient-derived cells and biomaterials.